A post hoc analysis presented at CCR West found sarilumab outperformed adalimumab and placebo in HbA1c improvement in rheumatoid arthritis patients with diabetes.
Beni Toure
Advertisement
Articles by Beni Toure
The JAK inhibitor previously approved for rheumatoid arthritis has reported early primary endpoint outcomes in its ongoing phase 3 trial.
Advertisement
Latest Updated Articles
Baricitinib Hits 16-Week Marks for Atopic DermatitisPublished: August 24th 2019 | Updated:
For HbA1c in RA Patients, Sarilumab Outperforms Adalimumab, PlaceboPublished: September 29th 2019 | Updated:
Advertisement
Advertisement